In short
Hormone imbalance is not a diagnosis. It is a description of symptoms that usually turn out to have a specific, nameable cause. In women under 45 with irregular or absent periods, the usual answers are polycystic ovary syndrome, a hypothalamic cause such as low energy availability or stress, raised prolactin, thyroid disease, or primary ovarian insufficiency. Each is found with a short, targeted set of tests taken at the right point in the cycle, and each is treated differently. A broad hormone panel taken at a random time answers none of them. Saliva hormone testing is not used.
Treatment Overview
Is hormone imbalance a real diagnosis?
No. Hormone imbalance is a description, not a diagnosis, and the work is to replace it with a specific one.
The symptoms that bring women in, irregular or absent periods, acne, unwanted hair growth, hair thinning, weight change, fatigue, low mood and difficulty conceiving, are real and often do have an endocrine cause. But they point to particular conditions with particular treatments, and calling the whole group an imbalance leaves you no closer to any of them.
It also opens the door to treatment aimed at a number rather than at a cause, which is how women end up on hormone preparations that neither address the underlying problem nor were needed.
Which tests are actually worth doing?
A short, targeted set. For a woman with irregular or absent periods, the standard evaluation is a pregnancy test, prolactin, thyroid-stimulating hormone and FSH, with more added according to what the history suggests.
| Test | What it distinguishes |
|---|---|
| hCG | Pregnancy, which is the first thing to exclude in absent periods |
| Prolactin | A raised prolactin, which can come from a pituitary cause or from medication |
| TSH and free T4 | Thyroid disease, which disrupts cycles in both directions |
| FSH and LH | High FSH points to the ovary, low or normal FSH points to the hypothalamus or pituitary |
| Total testosterone, SHBG | Androgen excess, relevant where there is acne, hair growth or hair thinning |
| Glucose or HbA1c, lipids | Metabolic features that travel with polycystic ovary syndrome |
What is not on that list matters as much. Ovarian reserve markers such as AMH and antral follicle count are used in fertility care and are not validated for determining menopausal status, and a broad panel of every available hormone taken at a random time is more likely to produce an incidental abnormal value than an answer.
Does the day of your cycle matter?
For some tests, a great deal. FSH, LH and oestradiol are interpreted against the early follicular phase, the first few days of a cycle, and mean something different taken elsewhere.
Progesterone is the clearest example: it is measured in the second half of the cycle, about a week before the next period is expected, because its purpose is to show whether ovulation happened. Taken at any other point it shows nothing useful.
Prolactin and thyroid function can be taken at any point in the cycle, although prolactin rises with stress, sleep, exercise and nipple stimulation, so a single mildly raised value is repeated before it is acted on.
Where periods are absent altogether, cycle timing does not apply and the tests are taken as they are, which is one reason absent periods are sometimes easier to work up than irregular ones.
What does it usually turn out to be?
In women under 45 with disrupted cycles, the common answers are polycystic ovary syndrome, a hypothalamic cause, raised prolactin, thyroid disease, or primary ovarian insufficiency.
- Polycystic ovary syndrome: irregular or absent cycles with features of androgen excess such as acne or hair growth, often with metabolic features. Treatment depends on whether the immediate goal is cycle regulation, skin and hair symptoms, or conception.
- A hypothalamic cause: low energy availability, heavy training, significant weight loss or sustained stress can switch off the signal from the brain. FSH and LH are low or normal rather than high. The treatment is the cause, not a hormone.
- Raised prolactin: can come from a pituitary adenoma or from medication, and both are identified and treated specifically.
- Thyroid disease: both under- and overactivity disrupt cycles, and both are treated in their own right.
- Primary ovarian insufficiency: menopause before 40, which needs a full assessment of its own.
Two of those, the hypothalamic group and thyroid disease, resolve when the cause is addressed. That is a better outcome than managing symptoms with hormones indefinitely, and it is the reason the sequence runs diagnosis first.
What if your periods stopped before 40?
Periods stopping before 40 is primary ovarian insufficiency, and it is assessed as its own condition rather than as early menopause.
The distinction is not academic. Women with primary ovarian insufficiency need hormone therapy continued at least to the average age of menopause, around 50 to 51, to reduce the risks of premature bone loss, coronary heart disease, stroke and dementia. Data from the Women’s Health Initiative, which studied older postmenopausal women, should not be applied to this group, and the doses used are higher than in standard menopause treatment.
Between 40 and 45 the picture sits in between, and the same evaluation as for any woman with irregular cycles is done: hCG, prolactin, TSH and FSH.
Over the age of 45 the diagnosis is made from your cycle pattern and your symptoms. A hormone blood test adds nothing and can mislead. Why blood tests are not used.
What if everything comes back normal?
Then the answer is outside the endocrine system, and that is a result rather than a dead end.
Sleep, training load and energy intake, stress, weight change, iron status and mood account for a large share of these symptoms in women whose hormone tests are clean, and all of them respond to attention. Where the leading complaint is fatigue or low mood rather than the cycle itself, those are worth assessing in their own right.
What does not follow from normal results is a course of hormones to see whether it helps.
What is not used here?
Saliva hormone testing, broad direct-to-consumer hormone panels as a first step, and compounded hormone preparations.
Saliva testing has no evidence base for guiding treatment. Broad panels taken at a random point in the cycle generate incidental abnormalities that then need explaining away. Compounded preparations have no randomised trials of efficacy or safety and no oversight of their contents or dose.
Compounded hormone mixtures and saliva testing are not used here, and the reason is not brand preference. What is wrong with compounded hormones.
Hormone assessment for younger women in Dubai and the UAE
What the local data show about polycystic ovary syndrome
Recorded diagnoses in Dubai are well below what community studies of polycystic ovary syndrome usually report, and they are rising.
A study of 64,722 women aged 15 to 45 at Latifa Women and Children Hospital in Dubai found a period prevalence of 1.6 percent of coded diagnoses over five years, with the annual figure rising from 1.19 percent in 2020 to 2.72 percent in 2022.
That is a count of diagnoses recorded in hospital records, not a measure of how many women have the condition, so it should not be read as the true prevalence. It is consistent with polycystic ovary syndrome being under-recognised rather than rare, and with recognition improving. For a woman here with irregular cycles, acne or unwanted hair growth, it is a reason to have it assessed properly rather than to assume it has already been ruled out.
Hormone panels sold directly to patients
Broad hormone panels are easy to buy in Dubai, and a panel is not an assessment.
Three problems come up repeatedly. The sample is taken at whatever point in the cycle is convenient, which makes FSH, LH, oestradiol and progesterone hard to interpret. Reference ranges belong to the laboratory that produced them and cannot be carried across to another. And a panel that includes twenty analytes will usually return one outside the range by chance, which then drives further testing rather than an answer.
Where a panel has already been done, it is used for what it is worth rather than discarded, and repeated only where the timing or the method makes it uninterpretable.
Who Is a Good Candidate?
- Women under 45 with irregular or absent periods who want a named diagnosis rather than a hormone panel.
- Women with acne, unwanted hair growth or hair thinning alongside cycle changes.
- Women whose periods stopped during heavy training, significant weight loss or a period of sustained stress.
- Women who have had a hormone panel done privately and want it interpreted properly.
- Women whose periods stopped before 40, which needs assessment as primary ovarian insufficiency.
- Absent periods with a possibility of pregnancy: this is excluded first.
- A request for a broad hormone panel with no symptoms and regular cycles: not recommended.
- Saliva hormone testing or compounded hormone preparations: not used.
What Happens During the Consultation
-
1
Your cycle history in detail
When periods started, what they were like, when and how they changed, whether they stopped, and what else was happening at the time: weight, training, stress, illness, travel, contraception.
-
2
The rest of the picture
Acne, hair growth or thinning, milk discharge, headaches or visual change, weight, thyroid symptoms, mood, sleep, medicines, and whether conception is a current goal.
-
3
Examination and targeted tests
Examination, then hCG, prolactin, TSH and free T4, FSH and LH, with testosterone and SHBG, glucose or HbA1c and lipids where indicated. Timed to the cycle where the timing changes the meaning.
-
4
A named diagnosis and a plan
The specific condition, or a clear statement that the endocrine tests are normal and what that redirects to. Where the pituitary is implicated, further assessment or imaging follows.
Program Structure & Follow-Up
How long does the assessment take?
Usually two to four weeks, because some tests have to be timed:
- Visit one: history, examination, and the tests that can be taken at any point.
- Within the cycle: the timed tests, where cycles are still happening.
- Visit two: results together, the diagnosis, and the plan.
Where periods are absent, the timed tests do not apply and the answer usually comes faster.
Contact between appointments runs through the membership programmes.
What follows the diagnosis
It depends entirely on which diagnosis it is, and that is the point of making one:
- Polycystic ovary syndrome: treatment aimed at the immediate goal, whether that is cycle regulation, skin and hair symptoms, metabolic risk or conception.
- A hypothalamic cause: energy availability, training load, weight and stress addressed, because that is what restores the signal.
- Raised prolactin: the cause identified and treated specifically.
- Thyroid disease: treated in its own right, after which cycles usually settle.
- Primary ovarian insufficiency: hormone therapy planned to continue to around the average age of menopause.
Benefits, Limits & Safety
What hormone testing cannot tell you
It cannot tell you when your menopause will be, and it cannot grade your fertility into a single number.
AMH and antral follicle count describe ovarian reserve in the context of assisted reproduction. They are not validated for predicting menopausal status, and a low result is not a diagnosis.
Why not simply take more hormones?
Because in most of these conditions the hormone level is a consequence rather than the problem.
In a hypothalamic cause, the signal from the brain has switched off for a reason, and replacing the downstream hormone leaves that reason in place. In polycystic ovary syndrome the issue is not a deficiency at all. Treating the number can mask the condition while it continues, and in a woman hoping to conceive it can delay the treatment that would actually help.
When should you seek assessment sooner?
Some features move a cycle problem up the queue:
- Periods stopping before 40.
- Milk discharge from the breasts, or headaches with visual changes, which point to the pituitary.
- Rapidly increasing hair growth, voice change or marked muscle development, which need prompt assessment.
- Absent periods with a possibility of pregnancy.
- Heavy or prolonged bleeding, particularly with tiredness or breathlessness.
In the UAE, call 998 for an ambulance in an emergency.
What the assessment achieves
A named diagnosis such as polycystic ovary syndrome, a hypothalamic cause, raised prolactin, thyroid disease or primary ovarian insufficiency, or a clear statement that the endocrine tests are normal and what that redirects to.
What is tested, and when
hCG, prolactin, TSH and free T4, FSH and LH, with testosterone, SHBG, glucose and lipids where indicated. FSH, LH and oestradiol read against the early follicular phase, progesterone in the second half of the cycle.
What is not used
Saliva hormone testing, broad direct-to-consumer panels as a first step, ovarian reserve markers to determine menopausal status, and compounded hormone preparations.
Cost & Program Investment
The assessment covers the consultation, examination, the targeted blood tests and the appointment where results are explained, and what that comes to is set out before anything is booked. Treatment costs depend on which diagnosis is made. Ongoing care runs through the membership programmes.
Frequently Asked Questions
No. It is a description of symptoms. The work is to replace it with a specific diagnosis such as polycystic ovary syndrome, a hypothalamic cause, raised prolactin, thyroid disease or primary ovarian insufficiency, because each is treated differently.
It depends on the test. FSH, LH and oestradiol are interpreted against the first few days of a cycle. Progesterone is measured in the second half, about a week before the next period is due, to show whether you ovulated. Prolactin and thyroid tests can be taken at any point.
Not if your cycles are regular and you have no symptoms. A broad panel taken at a random point in the cycle is more likely to produce an incidental abnormal value than an answer, and that then drives more testing rather than a diagnosis.
Then the cause is outside the endocrine system, which is useful to know. Sleep, training load and energy intake, stress, weight change, iron status and mood account for a large share of these symptoms in women with normal hormone tests, and all respond to attention.
Yes. Low energy availability, heavy training, significant weight loss or sustained stress can switch off the signal from the hypothalamus. FSH and LH are low or normal rather than high. The treatment is the cause rather than a hormone, and cycles usually return when it is addressed.
No. It has no evidence base for guiding treatment. Dosing steered by saliva testing is a feature of compounded hormone programmes rather than of standard practice.
It is assessed as primary ovarian insufficiency, which is its own condition. It matters because hormone therapy is then continued at least to around the average age of menopause, 50 to 51, at higher doses, to reduce the risks of premature bone loss, heart disease, stroke and dementia.
AMH and antral follicle count describe ovarian reserve for fertility care. They are not validated for determining menopausal status and a low result is not a diagnosis in itself. What it means depends on your age, your cycles and whether you are trying to conceive.
A study of 64,722 women aged 15 to 45 at Latifa Women and Children Hospital in Dubai recorded a period prevalence of 1.6 percent over five years, rising from 1.19 percent in 2020 to 2.72 percent in 2022. That counts recorded diagnoses rather than how many women have the condition, and suggests it is under-recognised rather than rare.
Not necessarily. It is used for what it is worth. It is repeated only where the timing in your cycle or the method makes it uninterpretable, and reference ranges from one laboratory are not applied to results from another.
Evidence
Where this information comes from
Every figure on this page is taken from the sources below. All of them are free to read, so you can check them yourself.
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
- Prevalence of Polycystic Ovary Syndrome amongst Females Aged between 15 and 45 Years at a Major Women's Hospital in Dubai, United Arab Emirates
- Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement
- The 2022 hormone therapy position statement of The North American Menopause Society
- Vitamin D status among apparently healthy individuals in the UAE: a systematic review
This page is general medical information and does not replace a personal consultation. Trial results are averages across large groups, not a prediction for any one person.